A survey of U.S. adults fielded from August 20 to September 16, 2024, found that approximately 14 percent of respondents reported symptoms of depressive disorder in the last two weeks. This survey has been running since the beginning of the COVID-19 pandemic and found an increased share of people reporting symptoms of depression during the first year of the pandemic. Symptoms of depression can include, but are not limited to, feelings of sadness and hopelessness, a loss of interest in things once found pleasurable, sleep disturbances, anxiety, tiredness, and a change in appetite. Differences in depression among men and women Although rates of suicide are much higher among men than women in the United States, women are more likely to suffer from depression than men. Surveys from 2020 to 2023, found that women constantly reported symptoms of depressive disorder more often than men, although the difference varied from a few percentage points to decimal points. However, in 2021, around 10 percent of women reported having a major depressive episode in the past year, compared to six percent of men. Major depressive episodes are most common among women aged 18 to 25 years. How many people receive treatment for depression? In 2021, it was estimated that around 11.5 million people in the United States with a major depressive episode received treatment. The most common professionals seen for a major depressive episode were general practitioners or family doctors, psychiatrists or psychotherapists, and counselors. However, many people with depression and other mental health problems do not receive treatment for various reasons. In 2021, cost was the number one reason U.S. adults stated they did not receive the mental health treatment they needed.

A survey of college students in the United States in 2023-2024 found that around 38 percent had symptoms of depression. Symptoms of depression vary in severity and can include a loss of interest/pleasure in things once found enjoyable, feelings of sadness and hopelessness, fatigue, changes in sleep, and thoughts of death or suicide. Mental health among college students Due to the life changes and stress that often come with attending college, mental health problems are not unusual among college students. The most common mental health problems college students have been diagnosed with are anxiety disorders and depression. Fortunately, these are two of the most treatable forms of mental illness, with psychotherapy and/or medications the most frequent means of treatment. However, barriers to access mental health services persist, with around 22 percent of college students stating that in the past year financial reasons caused them to receive fewer services for their mental or emotional health than they would have otherwise received. Depression in the United States Depression is not only a problem among college students but affects people of all ages. In 2021, around ten percent of those aged 26 to 49 years in the United States reported a major depressive episode in the past year. Depression in the United States is more prevalent among females than males, but suicide is almost four times more common among males than females. Death rates due to suicide in the U.S. have increased for both genders in the past few years, highlighting the issue of depression and other mental health disorders and the need for easy access to mental health services.

These are peer-reviewed supplementary tables for the article 'Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: MDD ICD-9/10 diagnosis codesSupplementary Table 2: Factors influencing likelihood of treatment inertia in patients with elevated PHQ-9 scoreAim: Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after treatment. Treatment inertia is the continued use of the same pharmacotherapy regimen when treatment goals are not met. This study assessed the frequency of treatment inertia among adult patients with MDD treated in a real-world setting. Patients & methods: This was a retrospective, observational study of patients with MDD identified in the Decision Resources Group Real World Evidence US Data Repository from January 2014 to June 2018. Patients (≥18 years) had an elevated Patient Health Questionnaire-9 (PHQ-9) score (≥5) following 8 weeks of stable baseline antidepressant use with/without mental-health outpatient therapy. Treatment inertia, modification and discontinuation were evaluated over a 16-week follow-up period (timeline based on the APA Practice Guidelines). The primary outcome was the proportion of MDD patients experiencing treatment inertia. Results: 2850 patients (median age, 55 years; 74% female) met the study criteria. Of these patients, 834 (29%) had study-defined treatment inertia, 1534 (54%) received treatment modification and 482 (17%) discontinued treatment. Use of mirtazapine (Odd ratio [OR]: 0.63; 95% confidence interval [CI]: 0.50–0.79), selective serotonin reuptake inhibitors (OR: 0.64; 95% CI: 0.54–0.75) or bupropion (OR: 0.71; 95% CI: 0.60–0.84) in the baseline period was associated with an increased likelihood of treatment modification versus not receiving treatment with these medications. Frequency of treatment inertia may differ among those who do not have a documented PHQ-9 score. Conclusion: Effective symptom management is critical for optimal outcomes in MDD. Results demonstrate that treatment inertia is common in MDD despite guidelines recommending treatment modification in patients not reaching remission.

Snapshot img

Treatment Resistant Depression Therapeutics Market Size 2025-2029

The treatment resistant depression therapeutics market size is forecast to increase by USD 2.06 billion at a CAGR of 6.1% between 2024 and 2029.

The market is experiencing significant growth due to the high prevalence of mental health disorders, such as depression, in the US population. The emergence of advanced technologies, like artificial intelligence, in drug development is also driving pipeline development in this market. However, the high cost of treatment remains a major challenge, leading to a need for innovative solutions. Combination therapy and somatic therapies are gaining popularity as effective treatment options for those with treatment-resistant depression. Clinical guidelines recommend these approaches for patients who have not responded to traditional antidepressant medications. Furthermore, the market is witnessing an increase in the number of patent filings for new treatment modalities, providing opportunities for pharmaceutical companies to expand their offerings. The market is particularly relevant to individuals suffering from chronic conditions, such as fibromyalgia and chronic pain, who often experience depression as a co-occurring condition. Overall, the market is poised for growth, with a focus on developing effective and affordable treatment options for those in need.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market represents a significant challenge in mental health care due to the limited efficacy of current antidepressant medications for individuals experiencing major depressive episodes. TRD, also known as treatment-resistant major depression, is a subtype of major depressive disorder (MDD) that does not respond to two or more trials of adequate doses of antidepressant medications of appropriate classes. TRD is a complex condition that often results in poor treatment adherence, increased healthcare utilization, and higher risk for hospitalization, suicidal ideation, and psychotic symptoms. According to the Anxiety and Depression Association of America, approximately one-third of individuals diagnosed with MDD experience TRD, making it a critical area of focus for drug development. Pharmacological treatment remains the primary approach for managing TRD. Antidepressants, which are typically administered through oral, intravenous, or nasal routes, have shown limited success in treating TRD. However, recent advancements in TRD therapeutics include the use of esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, which is administered nasally. Esketamine has shown promising results in clinical trials, providing rapid and sustained antidepressant effects in TRD patients. Despite these advancements, there is a need for alternative treatment approaches to address the complexities of TRD. Nonpharmacological treatments, such as electroconvulsive therapy (ECT), psychotherapy, and transcranial magnetic stimulation, have shown potential in managing TRD.
Combination therapies, which involve the use of multiple treatment modalities, are also being explored to improve treatment outcomes. The market is witnessing a steady product pipeline, with several drugs in various stages of development. These drugs target various mechanisms involved in TRD, including neuroplasticity, neuroinflammation, and neurotransmission. Drug approval processes are ongoing, and successful approvals could significantly impact the market. Mental health disorders, including TRD, have a substantial impact on healthcare access and suicide statistics. According to the National Institute of Mental Health, suicide is the 10th leading cause of death in the US, with depression being a significant risk factor.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Distribution Channel

  Offline
  Online


Type

  Antidepressants
  NMDA
  Antipsychotics
  Others


Geography

  North America

    US


  Europe

    Germany
    UK
    France
    Spain


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period.

Treatment-resistant depression (TRD) is a significant challenge in healthcare access, affecting a substantial number of individuals with major depressive disorders and other depression subtypes, including generalized anxiety disorder. According to statistics, suicide is a tragic consequence for some patients with TRD who do not respond to traditional antidepressant therapies. To address this unmet medical need, the product pipe

Snapshot img

Eczema Therapeutics Market Size 2024-2028

The eczema therapeutics market size is forecast to increase by USD 5.81 billion at a CAGR of 10.28% between 2023 and 2028.

The market is experiencing significant growth due to the high prevalence of atopic dermatitis, a common form of eczema. According to the American Academy of Dermatology, atopic dermatitis affects approximately 10-20% of children and 1-3% of adults in the United States alone. This presents a substantial market opportunity for companies developing innovative therapeutic solutions. Another key trend driving market growth is the rising adoption of telemedicine platforms in eczema therapeutics. The COVID-19 pandemic has accelerated the adoption of telemedicine, allowing patients to consult with healthcare professionals remotely and receive prescriptions for eczema treatments. This not only increases accessibility to care but also reduces the burden on healthcare systems and enables faster response times. However, the market is not without challenges. Stringent regulatory guidelines for eczema therapeutics pose significant barriers to entry for new players. Regulatory agencies such as the FDA require extensive clinical trials and rigorous testing to ensure the safety and efficacy of new treatments. Companies must invest heavily in research and development to navigate these regulations and bring new products to market. In conclusion, the market is poised for growth due to the high prevalence of atopic dermatitis and the increasing adoption of telemedicine. However, companies must navigate stringent regulatory guidelines to bring innovative treatments to market and capitalize on this opportunity. By focusing on research and development and leveraging telemedicine platforms, companies can effectively address the unmet needs of the growing eczema patient population and differentiate themselves in a competitive market.

What will be the Size of the Eczema Therapeutics Market during the forecast period?

Request Free SampleThe market encompasses the production and sale of treatments for skin disorders, particularly itchy skin conditions like eczema and atopic dermatitis. Symptoms include redness, inflammation, and rashes, affecting the skin barrier and immune system. Topical steroids, such as ointments and steroid creams, are common treatments for reducing inflammation. Genetics play a role in the development of these conditions, with atopic dermatitis being the most common type. Antihistamines are also used to alleviate symptoms, while the market continues to explore innovative solutions. Market dynamics include increasing prevalence due to genetic and environmental factors, as well as growing demand for non-steroidal alternatives. Key trends include the development of targeted therapies and the integration of technology for improved patient care.

How is this Eczema Therapeutics Industry segmented?

The eczema therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ApplicationAtopic dermatitisContact dermatitisOther indicationDistribution ChannelHospital and clinicsOnline pharmaciesRetail pharmaciesGeographyNorth AmericaUSCanadaEuropeGermanyUKAPACChina

By Application Insights

The atopic dermatitis segment is estimated to witness significant growth during the forecast period.Atopic dermatitis, a chronic inflammatory skin disorder affecting around 10% of the global population, is a common type of eczema that can persist from childhood into adulthood. Characterized by intense itching, redness, and skin irritation, this non-contagious condition is more prevalent in developed countries and urban areas. The immune system plays a significant role in its development, with contributing factors including genetics, environmental allergens, and stress. Medical therapies for atopic dermatitis include topical treatments like emollients, steroid creams, and PDE4 inhibitors, as well as injectable corticosteroids and immunomodulators like interleukin inhibitors. Antihistamines and antibiotics are also used to alleviate symptoms such as itching and skin infections. Probiotics have shown promise in improving the skin barrier function and reducing inflammation. Skin irritants like harsh soaps, detergents, and certain foods can trigger flare-ups. Hand sanitizers, although essential for maintaining hygiene, can also contribute to dryness and irritation. Roseomonas mucosa, a bacterium commonly found on the skin, may exacerbate symptoms in individuals with atopic dermatitis. Online pharmacies offer convenience for patients seeking access to steroid medicines and other treatments for atopic dermatitis. However, it is essential to consult with healthcare professionals for proper diagnosis and treatment plans to ensure the mo

Snapshot img

Neuropathy Pain Treatment Market Size 2024-2028

The neuropathy pain treatment market size is forecast to increase by USD 5.84 billion at a CAGR of 10.96% between 2023 and 2028.

The market is experiencing significant growth due to the presence of a large patient pool suffering from neuropathy pain. Neuropathy, a condition characterized by nerve damage, affects millions worldwide, leading to chronic pain, numbness, and weakness. A key trend influencing market growth is the development of topical patches for neuropathy pain treatment, offering patients a non-invasive alternative to traditional methods, alongside the increasing availability of generic drugs and the rise of e-pharmacies, providing convenient access to affordable treatment options. However, the high cost of neuropathy pain treatment remains a major challenge, limiting access to care for many patients. Despite this, ongoing research and development efforts are expected to yield new and more affordable treatment options, driving market expansion.

What will be the Size of the Neuropathy Pain Treatment Market During the Forecast Period?

Request Free Sample

Neuropathy pain, characterized by algiax pharmaceuticals' definition as 'damage or dysfunction of the somatosensory nervous system,' causes significant discomfort and symptoms such as hyperalgesia. The market is projected to grow, driven by the increasing prevalence of diabetes leading to the diabetic neuropathy segment. Phase studies are underway for investigational drugs like Vertex Pharmaceuticals Incorporated's Vixotrigine, an anticonvulsant In the drug class.



The pain management market covers retail pharmacies and drug stores. Tricyclic antidepressants are currently used, but new treatments are needed due to the aetiology and anatomic localization of neuropathy. The National Institutes of Health (NIH) and World Health Organization (WHO) are conducting research, as published in PubMed and Springer. Biogen, Baxter Healthcare, and Senzer Pharmaceuticals are also involved in developing new treatments. Data monitoring committees ensure the safety and efficacy of these projects In the in-depth report coverage of the pain management market.

How is this Neuropathy Pain Treatment Industry segmented and which is the largest segment?

The neuropathy pain treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Indication

  Diabetic neuropathy
  Chemotherapy-induced neuropathy pain
  Postherpetic neuralgia
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Indication Insights

The diabetic neuropathy segment is estimated to witness significant growth during the forecast period.

Neuropathic pain, a type of chronic pain caused by damage or dysfunction to the somatosensory nervous system, affects an estimated 10 million people worldwide, with a significant number being diabetic patients. Diabetic neuropathy, a common complication of diabetes, is characterized by aetiologies such as axonal damage, hyperalgesia, allodynia, and anatomic localization. Neuropathic pain can be caused by various conditions, including autoimmune diseases, virally-induced neuropathy, and oncology medications like chemotherapy. The pain management market for neuropathic pain is projected to experience significant growth due to the rising prevalence of diabetes and the increasing number of approved drugs for its treatment.

Furthermore, neuropathic pain medications include tricyclic anti-depressants, anticonvulsants such as Lyrica, Topamax, and Lamotrigine, and prescription opioids. However, these medications come with severe adverse effects and high costs, limiting their widespread use. The pain management market covers both pharmaceutical companies and pain management centres. Leading pharmaceutical companies are investing in research and development to bring new treatments to market. Guidelines recommend early diagnosis and treatment of neuropathic pain to prevent further nerve damage and provide symptomatic relief. Despite advancements in treatment, challenges remain, including the need for more effective and affordable options for the general population.

Get a glance at the Neuropathy Pain Treatment Industry report of share of various segments Request Free Sample

The diabetic neuropathy segment was valued at USD 2.96 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 33% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained

Market Overview:

The 7 major dysautonomia markets reached a value of US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 9.22% during 2024-2034.

The dysautonomia market has been comprehensively analyzed in IMARC's new report titled "Dysautonomia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysautonomia is a medical condition characterized by impairment or dysfunction of the autonomic nervous system. The autonomic nervous system controls and regulates involuntary bodily functions, such as blood pressure, heart rate, digestion, temperature regulation, bladder and bowel control, etc. Some of the common symptoms associated with the ailment are dizziness, lightheadedness, fainting or near-fainting episodes, rapid or irregular heart rate, excessive or lack of sweating, constipation, fatigue, cognitive impairment, problems with body temperature regulation, etc. Various other indications may include headaches, sleep disturbances, anxiety, difficulty concentrating, muscle weakness, fluctuations in blood pressure, etc. The diagnostic process typically begins with a thorough medical history and physical examination, where the healthcare provider will assess symptoms and look for signs of autonomic dysfunction. Numerous specialized tests, including autonomic function tests, such as tilt table testing, autonomic reflex testing, quantitative sudomotor axon reflex testing, etc., are also conducted. Additional diagnostic procedures, including blood investigations, imaging studies, neurological assessments, cardiac evaluations, etc., may be utilized to rule out other potential causes and evaluate overall autonomic function.

https://www.imarcgroup.com/CKEditor/4dedb3df-1d8a-4851-9909-836f756f69a8dysautonomia-market-report-(1).webp" style="height:450px; width:800px" />

The increasing cases of gene mutations that predispose individuals to autonomic nerve malfunction or degeneration are primarily driving the dysautonomia market. In addition to this, the rising prevalence of several associated risk factors, such as neurodegenerative disorders, chronic infections, physical trauma or injury to the autonomic nerves or spinal cord, diabetic neuropathy, etc., is acting as another significant growth-inducing factor. Moreover, the inflating demand for neurostimulation techniques, including deep brain stimulation (DBS) and spinal cord stimulation (SCS), which involve the implantation of electrodes that deliver controlled electrical impulses to targeted areas of the nervous system, thereby modulating its activity and alleviating autonomic dysfunction, is further creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in R&D activities to introduce medications that target specific neurotransmitter receptors, modulate ion channels, and enhance autonomic function. This, in turn, is also bolstering the market growth. Furthermore, the emerging popularity of gut microbiome interventions, such as fecal microbiota transplantation, etc., since they aid in restoring gut dysbiosis, reducing inflammation, and improving autonomic function, is expected to drive the dysautonomia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dysautonomia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for dysautonomia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysautonomia market in any manner.

Key Highlights:

• Dysautonomia is a relatively prevalent illness affecting over 70 million people globally.
• It can be present at birth (congenital) or develop at any time in life, with the usual age of onset being 50 to 60.
• Dysautonomia affects approximately 20% of the diabetic population.
• Dysautonomia affects more than one-third of Guillain-Barré syndrome patients and is more common in those with severe weakness.
• According to current survival statistics, a newborn with familial dysautonomia has a 50% chance of living to the age of forty.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dysautonomia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dysautonomia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dysautonomia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the dysautonomia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dysautonomia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dysautonomia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dysautonomia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysautonomia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysautonomia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with dysautonomia across the seven major markets?
• What is the size of the dysautonomia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dysautonomia?
• What will be the growth rate of patients across the seven major markets?
  

Dysautonomia: Current Treatment Scenario, Marketed Drugs and Emerging

Snapshot img

Irritable Bowel Syndrome Market Size 2024-2028

The irritable bowel syndrome market size is forecast to increase by USD 1.93 billion, at a CAGR of 9.3% between 2023 and 2028.

The Irritable Bowel Syndrome (IBS) market is experiencing significant growth, driven primarily by the increasing prevalence of this condition. Approximately 10-15% of the global population is affected by IBS, making it a substantial healthcare concern. Another key driver for market expansion is the increasing number of drug approvals for IBS treatments. However, the market faces challenges, including the side effects associated with existing generic medications. These adverse effects limit patient compliance and hinder market growth. As a result, there is a pressing need for the development of effective, side-effect-free treatments to cater to the growing patient population and improve patient outcomes.
Companies in the IBS market must focus on addressing these challenges through innovative research and development efforts to capitalize on the market's potential and meet the unmet needs of patients.

What will be the Size of the Irritable Bowel Syndrome Market during the forecast period?

Request Free Sample

The irritable bowel syndrome (IBS) market continues to evolve, driven by advancements in artificial intelligence (AI) and personalized medicine. These technologies are revolutionizing the way IBS is diagnosed and treated, with a focus on lifestyle modifications, fiber supplements, and patient education. Clinical trials exploring fecal microbiota transplantation and prescription medications offer promising solutions for managing symptoms, while precision medicine and patient advocacy groups facilitate better treatment outcomes. The consumer healthcare sector is embracing digital health, with wearable devices, mobile apps, and over-the-counter medications providing convenient solutions for managing IBS symptoms. Machine learning and data analytics are being integrated into medical technology to improve patient support and symptom management.

The ongoing unfolding of market activities reveals a shift towards a more holistic approach to gut health, incorporating stress management, dietary changes, and food intolerances. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are also being addressed through innovative treatments and patient education. The evolving patterns in the IBS market reflect a growing emphasis on patient satisfaction and quality of life, with medical devices and patient support groups playing essential roles in improving treatment experiences. The integration of AI and personalized medicine is expected to further transform the market, offering new opportunities for innovation and growth.

How is this Irritable Bowel Syndrome Industry segmented?

The irritable bowel syndrome industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  IBS-D
  IBS-C
  IBS-M


Drug Class

  Antibiotics
  Guanylate cyclase-C agonists
  Mu-opioid receptor agonists
  Chloride channel activators
  Antispasmodics
  Antidiarrheals
  Others


Distribution Channel

  Offline
  Online


Treatment Type

  Medications
  Dietary Supplements
  Therapeutics


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  APAC

    Australia
    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The ibs-d segment is estimated to witness significant growth during the forecast period.

Irritable Bowel Syndrome with Diarrhea (IBS-D) is a subtype of irritable bowel syndrome characterized by chronic, recurrent diarrhea, abdominal pain, bloating, and a sense of urgency. Patients with IBS-D often face unpredictable bowel movements, leading to significant disruptions in daily life and causing anxiety around mealtimes and travel. The unpredictability of symptoms can negatively impact quality of life, driving many patients to explore various treatment options. Treatment for IBS-D primarily focuses on managing diarrhea and abdominal pain while addressing underlying gut sensitivities. Lifestyle modifications, such as dietary changes and stress management, can help alleviate symptoms for some patients.

Fiber supplements and over-the-counter medications are commonly used to manage diarrhea and promote regularity. Prescription medications, like antispasmodics and antidepressants, may be recommended for managing abdominal pain and improving overall gut health. In the realm of medical innovation, artificial intelligence (AI) and machine learning are being explored to develop personalized treatment plans based on individual patient data. Clinical trials are underway to investigate the effic

Snapshot img

Throat Pastilles and Cough Drops Market Size 2024-2028

The throat pastilles and cough drops market size is forecast to increase by USD 1.25 billion, at a CAGR of 3.72% between 2023 and 2028.

The market is driven by the advantages these dosage forms offer over other traditional remedies. Throat pastilles and cough drops provide quick relief, allowing for localized action and easy consumption, making them a preferred choice for consumers seeking instant relief from throat irritation and coughing. Furthermore, the emergence of innovative throat pastilles and cough drops lozenges, infused with natural ingredients and flavors, caters to the growing demand for healthier and more palatable options. However, this market faces challenges related to the side effects and concerns surrounding excipients used in throat pastilles and cough drops. Excipients such as sorbitol, saccharin, and artificial flavors can cause adverse reactions in some consumers, including tooth decay and potential allergic reactions.
Addressing these challenges by formulating throat pastilles and cough drops with natural ingredients and minimal excipients can help companies differentiate themselves and cater to the evolving consumer preferences. This strategic approach will not only enhance product appeal but also enable companies to capitalize on the growing market potential for healthier and more effective throat relief solutions.

What will be the Size of the Throat Pastilles and Cough Drops Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample

The market continues to evolve, shaped by various market dynamics and applications across diverse sectors. Soothing agents, such as honey and menthol, are at the forefront of product innovation, offering consumers relief from sore throats and coughs. Manufacturers employ marketing strategies that emphasize health claims and FDA regulations, ensuring allergen information and cough suppression are clearly communicated. The manufacturing process involves sourcing ingredients, adhering to regulatory compliance, and managing production costs. Sugar-free options and antiseptic properties add value to the market, catering to consumer preferences and convenience. Direct-to-consumer sales and e-commerce platforms expand distribution channels, while expiration dates and packaging costs are crucial considerations.

Medicated candies, herbal remedies, and hard candies each hold a unique place in the market, with nutritional information and dosage forms playing a significant role in consumer decision-making. Regulatory compliance, profit margins, and product differentiation are essential aspects of new product development, as consumer demographics and pricing strategies evolve. Quality control, ingredient safety, and storage conditions are crucial elements of the supply chain, ensuring the shelf life and dissolution rate meet consumer expectations. Advertising regulations and product labeling are essential for maintaining consumer trust and regulatory compliance. The market's ongoing dynamism is reflected in the evolving patterns of retail sales, with mass market retailers and grocery stores offering a wide range of options.

The convenience of cough drops and throat pastilles, combined with their affordability and accessibility, make them a popular choice for consumers seeking relief from throat discomfort.

How is this Throat Pastilles and Cough Drops Industry segmented?

The throat pastilles and cough drops industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Hard tablet lozenges
  Soft tablet lozenges
  Compressed tablet lozenges


End-user

  Hospitals
  Clinics
  Others


Geography

  North America

    US
    Canada


  Europe

    Germany
    UK


  APAC

    Japan


  Rest of World (ROW)

By Type Insights

The hard tablet lozenges segment is estimated to witness significant growth during the forecast period.

Hard throat pastilles, also known as hard candy lozenges, are a popular form of medicated candy used for sore throat relief, cough suppression, and antiseptic properties. These lozenges are produced through a manufacturing process involving the heating and mixing of sugars and other ingredients with active components in a nanocrystalline state. The resulting product is a hard tablet that dissolves slowly in the mouth over a 5-10 minute period, releasing active ingredients for therapeutic benefits. Retail sales of throat pastilles and sugar-free cough drops continue to grow, driven by consumer demand for convenience and quick relief.

Ingredient sourcing and production costs are critical fa

Market Overview:

The 7 major functional dyspepsia markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.99% during 2024-2034.

The functional dyspepsia market has been comprehensively analyzed in IMARC's new report titled "Functional Dyspepsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Functional dyspepsia is a chronic digestive disorder characterized by recurrent and bothersome upper abdominal symptoms, despite no apparent structural abnormalities in the gastrointestinal tract. This condition affects the upper part of the digestive system, mainly the stomach, and can cause discomfort, pain, and a feeling of fullness during or after meals. The symptoms of the ailment commonly include persistent burning sensation or pain in the upper abdominal region, early satiety, bloating, belching, nausea, etc. These indications can significantly impact a patient's quality of life, leading to reduced appetite and potential weight loss. The diagnosis of functional dyspepsia typically involves a comprehensive medical history assessment, a physical examination, and possibly some tests to rule out various other conditions. These investigations may include blood workups, upper gastrointestinal endoscopy, and imaging studies. A crucial aspect of the diagnosis is the Rome criteria, which define the specific symptom patterns and duration required to classify the condition as functional dyspepsia.

https://www.imarcgroup.com/CKEditor/7de506c9-c7db-4c1c-affd-8baf2178e575functional-dyspepsia-market.webp" style="height:450px; width:800px" />

The rising incidences of several associated risk factors, such as irritable bowel syndrome, excessive alcohol consumption, cigarette smoking, use of non-steroidal anti-inflammatory drugs, etc., are primarily driving the functional dyspepsia market. In addition to this, the inflating utilization of effective medications, like proton pump inhibitors, H2 receptor antagonists, prokinetic agents, etc., to alleviate or ease symptoms as well as improve patients' overall quality of life is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications and dietary changes on account of their numerous advantages, including management of indigestion, prevention of disease progression, and enhancement of treatment outcomes, is further bolstering the market growth. Apart from this, the rising usage of non-pharmacological interventions that include stress reduction procedures and mindfulness practices to reduce stress, promote relaxation, and improve gastrointestinal health in individuals suffering from illness is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel therapeutic approaches, such as neuromodulation techniques and gut-targeted therapies, which mainly target the nervous system and gut function, thereby addressing the root causes of the disease and potentially offering more effective solutions for patients, is expected to drive the functional dyspepsia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the functional dyspepsia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for functional dyspepsia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the functional dyspepsia market in any manner.

Key Highlights:

• Functional dyspepsia affects more than 20% of the population.
• It most frequently occurs in the age ranges 16-30 years and 31-45 years, i.e. among young people.
• A study revealed that the prevalence of functional dyspepsia is substantially higher in low- and middle-income nations, 37.9%, than in high-income countries, 10%, with a higher proportion among the Afro-Caribbean race, 47.9%.
• In research conducted in the United States, the United Kingdom, and Canada, an average prevalence rate of 10% was recorded, with a higher frequency in the United States, at 12%.
• A meta-analysis of epidemiological research found that female sex, smoking, use of non-steroidal anti-inflammatory medicines (NSAIDs), and H. pylori infection were risk factors for the condition, but with a moderate correlation between them.

Drugs:

Acotiamide (Z-338 or YM443) is a novel medication under development for treating functional dyspepsia. This candidate is a gastroprokinetic medication that increases acetylcholine release in the enteric nervous system by antagonizing muscarinic receptors and inhibiting acetycholinesterase.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the functional dyspepsia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the functional dyspepsia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current functional dyspepsia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the functional dyspepsia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the functional dyspepsia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the functional dyspepsia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key

As of 2021, the states with the highest lifetime prevalence of asthma among adults included New Hampshire, Rhode Island, and Vermont. In New Hampshire and Rhode Island around 17.4 percent of adults self-reported that a doctor, nurse, or other health professional had told them that you had asthma at some pinot in their lifetime. Asthma is a chronic disease affecting the airways of the lungs that can be mild or severe and can cause shortness of breath, tightness or pain in the chest, coughing, and wheezing.

The prevalence of asthma in the United States Asthma in the United States is more common among men than women, with around 8.9 percent of women with current asthma in 2021, compared to 6.5 percent of men. Current asthma is also more common among adults than children, with those aged four years and below the least likely age group to suffer from the disease. It is unclear what exactly causes asthma; however it is believed that both environmental and genetic factors play a role. In 2021, non-Hispanic Blacks were more likely to report currently suffering from asthma than their non-Hispanic white and Hispanic counterparts.

Death from asthma Medicine for asthma can help control the disease in the long-term and provide short-term relief from symptoms. Therefore, deaths from asthma in the United States are rare, with it being the underlying cause of death in about one out of every 100,000 population. The states with the highest death rates from asthma are Mississippi, Hawaii, and Oregon. In 2020, there were a total of 4,145 deaths due to asthma in the United States.

In the United States between February 12 and March 16, 2020, the percentage of COVID-19 patients hospitalized with the disease increased with age. Findings estimated that up to 70 percent of adults aged 85 years and older were hospitalized.

Who is at higher risk from COVID-19? The same study also found that coronavirus patients aged 85 and older were at the highest risk of death. There are other risk factors besides age that can lead to serious illness. People with pre-existing medical conditions, such as diabetes, heart disease, and lung disease, can develop more severe symptoms. In the U.S. between January and May 2020, case fatality rates among confirmed COVID-19 patients were higher for those with underlying health conditions.

How long should you self-isolate? As of August 24, 2020, more than 16 million people worldwide had recovered from COVID-19 disease, which includes patients in health care settings and those isolating at home. The criteria for discharging patients from isolation varies by country, but asymptomatic carriers of the virus can generally be released ten days after their positive case was confirmed. For patients showing signs of the illness, they must isolate for at least ten days after symptom onset and also remain in isolation for a short period after the symptoms have disappeared.

A survey conducted in 2022 found that young adults aged between 18 and 24 were more likely to suffer from moderate to severe stress, depression, and anxiety symptoms. That year, around 66 percent of respondents from this age group reported stress-related symptoms, while 25 percent of those aged 65 and older had similar symptoms. Similar age group trends were also noted for negative effects on wellbeing from feelings of loneliness. Additionally, fewer men than women were likely to report having mental health conditions such as stress, anxiety, and depression. Anxiety, depression, and stress in Europe In Europe, there is a notable variation in the prevalence of mental illnesses. Throughout the epidemic, depression and anxiety increased in all EU nations, affecting young people, particularly young women and those in financial difficulties. A study published by the OECD reported that 55 percent of adults residing in the EU were at risk of depression in 2022. Another study, published in the same year, found that more than half of the respondents surveyed in Ireland, the United Kingdom, and Italy had reported experiencing stress. Anxiety, depression, and loneliness in the U.S. In the United States, anxiety, depression, and loneliness are prevalent issues affecting a significant portion of the population. According to a survey done in 2022, one-third of U.S. adults aged between 18 and 29 years mentioned that they “always” or “often” felt depressed or lonely in the past year. Over half of U.S. adults in the same age group reported that they felt anxious. Furthermore, adults with lower household incomes were more likely than those with higher household incomes to mention that they felt anxious, lonely, or depressed.

According to a recent Statista survey around 64 percent of those aged 18 to 30 years caught a cold 1 to 3 times in the past year. The common cold is a viral infection that affects the nose and throat and usually lasts from 1 week to 10 days. Common symptoms can include a runny nose, sore throat, cough, congestion, and sneezing.

Treatment

There is no cure for the common cold and antibiotics are not effective, so treatment focuses on relieving symptoms. Over-the-counter (OTC) pain relievers, decongestants and cough syrups are common treatments as well as home remedies such as drinking plenty of fluids and resting. According to a survey from Statista, the most common remedies for the common cold include, sleeping, eating soup, drinking tea, and staying home.

Prevention

The common cold is extremely contagious but commonsense measures can be taken to reduce one’s risk of contracting it. Measures to prevent the cold include regularly washing hands, using disinfectant, avoiding those who are sick, and generally eating well, exercising, and getting enough sleep. Even though the common cold is contagious and burdensome, around 40 percent of adults in the U.S. reported they went to work when they were sick within the last year.